horses is the Complement Fixation Test (CFT). However, studies have shown that CFT cannot differentiate between species of Trypanosoma as the CFT is not species specific [5] . The diagnostic significance of this test is therefore doubtful in countries where both T. equiperdum and T. evansi infections occur. Human sleeping sickness [6] caused by T. gambiense and surra in camels caused by T. evansi [2] can be diagnosed with T. equiperdum antigen. In collaboration with the Instituto G. Caporale, Teramo, Italy, we received 8 confirmed Dourine positive equine sera samples of different titres collected during the Italian outbreak in 2011 [4] . These 8 sera were further tested at CVRL using antigen preparations from 7 different T. equiperdum strains including ITMAS 170108 (OVI), ITMAS 070109 (Botat), ITMAS 261003B 943 (Ethiopian), ITMAS 220101 (American), ITMAS 211199A (French), ITMAS 241199B (German), ITMAS 290101 (Canadian), as well as T. evansi strain. T. evansi strain was isolated from a dromedary in Dubai [3] . The results of these investigations are summarized in Table 1 . As seen from the Table, 8 sera reacted with different titres against different T. equiperdum strains as well as T. evansi. This proves that standardization of T. equiperdum antigen for use in CFT is an important issue.
*The optimum dilution of T. evansi antigen for CFT testing has been obtained by performing checker board with T. evansi positive serum **The optimum dilution of different isolates of T. equiperdum antigen for CFT testing has been obtained by performing checker board with T. equiperdum positive serum. [1, 2] . Using BLAST, sequences were aligned with those deposited in GenBank for both piroplasms, having a minimum 98% query coverage and >97% homology. Genetic distance and homology confirmed that sequences of both parasites could be divided into the 3 groups, with a homology among the groups >97% [1, 2] . Group 1 included sequences homologous to first-ever reported piroplasms, group 2 to the "like genotypes" [1] , and group 3 included those with equidistant homology for the two groups [2] . Among the 72 sequences identified as T. equi, 39 belonged to group 1, 24 to group 2, and 9 to group 3. Group 1 included 62% (24/39) of the sequences of symptomatic horses, while 96% (23/24) of T. equi like (group 2), were from asymptomatic horses. Studies report that sequences within group 1 and 2 are in all endemic areas, while in America only group 1 and 3 are present. To date, sequences belonging to Group 3 were never submitted for Europe and Asia. Of the 27 T. equi PCRpos/ELISAneg samples, 23 (85.1%) had Group 1 sequences with 19 of them from symptomatic horses. For B. caballi, 7 sequences were obtained, of which only 2 were from horses positive for ELISA, 4 belong to group 1, 1 to group 2, and 2 to group 3. No clinical significance was attributed to this parasite due to the limited number of sequences available. Sequences within the same groups and their wide geographic distribution suggest that the diversity could be independent from their origin and probably linked with the international movement of equidae. The present study is the first to report group 3 for both parasites Table 1 CFT results of 8 Dourine-positive Italian horse sera using T. evansi and different strains of T. equiperdum antigens SAMPLE ID CVRL CFT CFT CVRL CFT ** (with different T. equiperdum strains)
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T. evansi* Teramo, Italy Ethiopian Ag Ovi Ag French Ag Canadian Ag German Ag BoTat Ag American Ag in Europe. Further studies are required to investigate the relatively low sensitivity of the ELISA and the possible correlation of the clinical evolution of the infection with the genetic group.
